3
Genetically mimicked effects of evinacumab on psoriasis: a drug target Mendelian randomization study
▪ Author : Zhihui Yang, Wendi Xiao, Zhenhuang Zhuang, Siyan Zhan, Mingyue Wang, Yan Wu, Tao Huang, Ruoyu Li
▪ Keyword : psoriasis, angiopoietin-like 3, evinacumab, lipid metabolism, Mendelian randomization
Background and Objectives: Dyslipidemia has been reported to contribute to
the psoriasis pathogenesis. Thus, evinacumab, a novel lipid-lowering drug
targeting angiopoietin-like 3, may have therapeutic potential to treat and/or
manage psoriasis. Methods and Study
Design: Summary statistics were obtained from genome-wide association
studies addressing psoriasis (FinnGen Consortium; n=216,752) and serum lipid
concentrations (United Kingdom Biobank; n=403,943–440,546). Two-sample
Mendelian randomization analyses were conducted to evaluate the associations of
serum lipid concentrations and genetically mimicked effects of evinacumab,
respectively, with the risks of psoriasis and its subtypes. Results:
Genetically determined per standard deviation increase in triglyceride
concentrations was associated with increased risk of psoriasis (OR: 1.17, 95%
CI: 1.03–1.32, p=0.018), whereas that in low-density
lipoprotein-cholesterol (LDL-C) was associated with both psoriasis (OR: 1.22,
95% CI: 1.05–1.43, p=0.011) and its subtypes, including arthropathic
psoriasis (OR: 1.30, 95% CI: 1.02–1.65, p=0.032), psoriasis vulgaris
(OR: 1.87, 95% CI: 1.16–2.99, p=0.0095), and guttate psoriasis (OR:
2.19, 95% CI: 1.17–4.07, p=0.014). Moreover, genetically mimicked
effects of evinacumab, via angiopoietin-like 3 inhibition, significantly
reduced the risk of psoriasis (OR: 0.752 per standard deviation reduction in
triglycerides, 95% CI: 0.577–0.982, p=0.036) and arthropathic psoriasis
(OR: 0.266 per standard deviation reduction in LDL-C, 95% CI: 0.0886–0.799, p=0.018). Conclusions: The genetically mimicked effect of evinacumab
has the potential to reduce the risk of psoriasis and arthropathic psoriasis by
lowering circulating triglyceride and LDL-C concentrations, respectively. These
findings suggest that evinacumab may help prevent psoriasis and psoriatic
arthritis progression in clinical practice.